Dr Reddy's Laboratories Ltd. said it won tentative approval from the US Food and Drug Administration for injectable lenacapavir, a long-acting HIV-1 prevention drug, adding a high-value biosimilars-adjacent asset to its regulated markets portfolio. Tentative status reflects patent litigation dynamics in the United States; the Hyderabad company can launch once legal exclusivities clear or settlements permit, a pathway it has navigated on prior complex injectables.
Clinical role
Lenacapavir belongs to the capsid inhibitor class, administered subcutaneously on schedules measured in months rather than daily pills, which public-health agencies view as adherence-friendly for pre-exposure prophylaxis programmes. US approval covers risk-reduction labeling developed in phase-3 trials; Indian regulators will consider separate filings under CDSCO rules before domestic PrEP guidelines expand beyond oral tenofovir combinations.
Manufacturing
Dr Reddy's will produce drug substance at its biotechnology park units with fill-finish lines qualified for US current good manufacturing practice audits completed earlier this year. Management told analysts export revenue from HIV therapies helps diversify beyond generic oral solids facing price erosion in US channels.
Access questions
Global health advocates watch pricing commitments for low-income markets; tentative FDA approval does not automatically trigger National AIDS Control Organisation procurement. For patients, the milestone is supply-side: an Indian manufacturer entering the lenacapavir supply chain can eventually reduce import dependence if policy makers add injectable PrEP to national formularies.
Regulatory timeline
Tentative approval letters specify patent dispute codes that lawyers monitor daily; Dr Reddy's legal team said it maintains dialogue with originator counsel consistent with prior complex injectable launches. CDSCO filing timelines for India were not disclosed, though company executives hinted at a separate bioavailability bridging study if regulators request local demographic data.
Commercial outlook
US PrEP markets already include oral generics; injectable lenacapavir targets patients failing daily adherence and clinics bundling prevention with primary care visits. Revenue models depend on payer coverage decisions expected after FDA label finalisation, not tentative status alone.